Look forward to an IPO in next 18-24 months, says Biocon’s Kiran Mazumdar Shaw

CNBC-TV18 2020-01-24

Views 56

Biocon reported its Q3 numbers and it was a mixed set. Revenue was in-line, up around 13.5 percent, but margins took a hit due to higher R&D and remediation expense on the Malaysia facility.
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
Q2WithBQ With Biocon's Kiran Mazumdar Shaw
play
16:17

Q2WithBQ With Biocon's Kiran Mazumdar Shaw
Profit Insights | Biocon's Kiran Mazumdar Shaw Exclusive | NDTV Profit
play
00:00

Profit Insights | Biocon's Kiran Mazumdar Shaw Exclusive | NDTV Profit
Corporate tax cut is a much needed reform, says Biocon's Kiran Mazumdar Shaw
play
02:22

Corporate tax cut is a much needed reform, says Biocon's Kiran Mazumdar Shaw
Biocon’s Kiran Mazumdar Shaw On Who’ll Win The Battle Between ‘Innovators’ And Biosimilar Makers
play
12:25

Biocon’s Kiran Mazumdar Shaw On Who’ll Win The Battle Between ‘Innovators’ And Biosimilar Makers
Biocon's Kiran Mazumdar Shaw On Syngene’s IPO
play
04:32

Biocon's Kiran Mazumdar Shaw On Syngene’s IPO
Pfizer supply brought forward over the next two months
play
02:45

Pfizer supply brought forward over the next two months
kiran-mazumdar-shaw-at-global-technology-summit
play
20:52

kiran-mazumdar-shaw-at-global-technology-summit
The Success Story of Kiran Mazumdar Shaw
play
03:49

The Success Story of Kiran Mazumdar Shaw
Kiran Mazumdar Shaw Chairman of Biocon India
play
04:17

Kiran Mazumdar Shaw Chairman of Biocon India
Q4 Review: Biocon's Kiran Mazumdar Shaw On Earnings & FY23 Projections
play
17:17

Q4 Review: Biocon's Kiran Mazumdar Shaw On Earnings & FY23 Projections
Kiran Mazumdar Shaw On Fighting and Recovering From COVID-19: ‘Dont Panic, Be Positive
play
02:12

Kiran Mazumdar Shaw On Fighting and Recovering From COVID-19: ‘Dont Panic, Be Positive
Kiran Mazumdar-Shaw | Compassionate capitalism
play
02:13

Kiran Mazumdar-Shaw | Compassionate capitalism